Page last checked
Prescription obstetric medicine · separate nasal-spray research
Oxytocin
Oxytocin doses depend on the care setting. Read the Pitocin label amounts and the nasal-spray trial, which found no benefit for its main measures.
- Pitocin label amounts depend on the type of care.
- The nasal-spray trial did not show a benefit over placebo.
- Injection and nasal-spray findings must stay separate.
Pitocin is a US brand of synthetic oxytocin. It is an injection. The checked product has 10 units in each milliliter.
It is made for infusion into a vein (IV) or injection into a muscle.
The Pitocin label covers specific care during or after pregnancy. These uses need medical monitoring. To induce labor, the label uses an IV infusion in a hospital.
After the placenta is delivered, its postpartum section also gives an amount to inject into a muscle. A separate team tested a nasal spray in children and teens with autism. That 24-week trial found no significant gain over placebo in social or cognitive function.
The injection and spray have different products, routes and study schedules.
What matters first
- What the US label covers: Pitocin can start or strengthen womb contractions when labor is medically needed. The label also covers its use alongside specified abortion care. After delivery, it can produce contractions or control bleeding.
- What the label does not cover: The label does not list elective labor induction without a medical need as a use. Its label does not cover a nasal spray to treat autism.
- Where it is given: To induce or strengthen labor, the label requires IV use in a hospital with adequate medical supervision. Other sections give IV or muscle-injection amounts for their own pregnancy-care settings.
- What the nasal-spray trial found: SOARS-B tested the spray for 24 weeks. People were aged 3 through 17 and had autism. The main and secondary benefit results generally did not differ from placebo.
- Keep activity units separate from mass: Units and IU measure activity. They cannot be turned into milligrams, micrograms or U-100 syringe marks here. These hospital and research schedules do not support a vial calculator.
Pitocin label amounts, kept with their clinical context
| Label use and setting | Route | Amount stated by the label | Boundary that stays beside it |
|---|---|---|---|
| Medically indicated induction or stimulation of labor in a hospital | Intravenous infusion | Initial rate 0.5–1 milliunit per minute; the label describes increases of 1–2 milliunits per minute at 30–60 minute intervals | The dose is individualized to uterine response. The label requires an infusion pump, continuous observation, uterine and fetal-heart-rate monitoring, and immediate stopping for uterine hyperactivity or fetal distress. This is a hospital protocol, not a consumer titration. |
| Control of postpartum uterine bleeding when an IV infusion is already running | Intravenous infusion | 10–40 units may be added to the remaining electrolyte or dextrose solution, with a maximum of 40 units in 1,000 mL | This is an amount added to an infusion bottle. The rate is adjusted to sustain uterine contraction and control uterine atony; the row does not turn the bottle amount into a fixed delivered dose. |
| Control of postpartum uterine bleeding after delivery of the placenta | Intramuscular injection | 10 units in 1 mL | This amount belongs only to the label’s postpartum setting. It is not the labor-induction infusion and not a nasal-spray amount. |
| After suction or sharp curettage for an incomplete, inevitable or elective abortion | Intravenous infusion | 10 units added to 500 mL of physiologic saline or 5% dextrose in water | The label says this infusion may help the uterus contract. The mixture amount is not presented as a fixed amount delivered to a patient. |
| Following specified intra-amniotic methods for midtrimester elective abortion | Intravenous infusion | 10–20 milliunits per minute; total not to exceed 30 units in 12 hours | The label ties the limit to water-intoxication risk. It is a separate clinical context and is not combined with the other rows. |
Concentration is not a dose
“10 units/mL” is the vial’s concentration. It is not the dose for every use. The label’s standard labor infusion starts with one 1-mL vial.
That vial holds 10 units. It is added to 1,000 mL of saline or Ringer’s lactate. The mixed fluid then has 10 milliunits per milliliter.
The labor dose is set as a rate in milliunits per minute.
Intranasal research stays separate
SOARS-B, NCT01944046, was a Phase 2 trial with random group assignment and a placebo control. It enrolled 290 children and teens with autism, aged 3 through 17. The paper’s benefit analysis included 277 people.
Of these, 139 were assigned to oxytocin and 138 to placebo.
| Research question and setting | Route | Studied amount | Result boundary |
|---|---|---|---|
| Social functioning in children and adolescents with autism; 24-week double-blind phase | Intranasal study spray | Target total 48 IU daily, typically 24 IU twice daily from week 8 | This was a flexible research protocol, not an approved dose or a personal-use schedule. The paper reports no significant benefit over placebo. |
The paper says dosing began at 8 IU each morning. The study team could adjust it. The paper also describes possible increases above the 48-IU target.
These could occur after seven weeks at that target. The registry gives a flexible, double-blind range of 8–80 IU per day. It also describes a later open-label phase with a changed formulation and maximum.
These details do not form one combined dose-escalation schedule. The table keeps only the 48-IU target from the published 24-week comparison.
What the trial found
At 24 weeks, the main social-withdrawal score changed by −3.7 with oxytocin and −3.5 with placebo. These are least-squares means. The difference between groups was −0.2 points.
Its 95% confidence interval was −1.5 to 1.0, and P was 0.61. Secondary outcomes generally did not differ. The authors found no gain over placebo in social interaction or the other measured parts of social function.
This negative result applies to the product, people and plan tested in SOARS-B. It does not make the Pitocin label evidence for nasal-spray use. It also does not set a spray dose for another purpose.
Safety and notice boundaries
The Pitocin label displays an Important Notice above its approved uses. It says not to induce elective labor without a medical need. The label’s XML files classify this as a Boxed Warning Section, with LOINC code 34066-1.
Both details matter: the visible title is “Important Notice,” and the formal label category is a boxed warning.
To induce or strengthen labor, the label requires IV use in a hospital with adequate medical supervision. Too much womb activity can harm the pregnant patient and fetus. The label also warns of water intoxication.
This is a risk especially with continuous infusion and fluid taken by mouth. Severe cases have included convulsions, coma and maternal death.
In SOARS-B, the overall rate and severity of adverse events were similar in both groups. That was one monitored trial in children and teens with autism. It does not establish a complete safety profile for the spray.
It also does not replace the pregnancy-care warnings for the injection.
Reader questions
What is the difference between oxytocin and Pitocin?
Oxytocin is the drug ingredient. Pitocin is the checked brand of synthetic oxytocin injection. Its vial has 10 units per milliliter.
The label covers specified care during or after pregnancy.
Is 10 units per milliliter the Pitocin dose?
No. It is the vial’s concentration. Label amounts and infusion rates differ by care setting.
The amount mixed into an infusion bottle is not always the amount delivered.
Is there one standard oxytocin dose?
No single number covers these sources. The Pitocin label separates labor induction, postpartum bleeding and abortion care. It says to adjust the labor dose to the womb’s response.
The SOARS-B spray amount comes from a separate study plan.
Is Pitocin a nasal spray for autism?
No. The checked Pitocin label is for an injection used in pregnancy-related care. SOARS-B used a different nasal spray to study autism.
Did nasal-spray oxytocin improve autism-related social functioning?
Not in SOARS-B. At 24 weeks, the main measure did not differ significantly from placebo. Secondary outcomes generally did not differ either.
How many milligrams are in an oxytocin unit or IU?
The dose sources use units, milliunits or IU to state activity. They do not support a conversion from activity to mass here. These amounts cannot be turned into milligrams or micrograms.
Can these amounts be used as home instructions?
No. Pitocin amounts belong to label protocols for specific monitored pregnancy-care settings. The spray amount comes from a controlled trial that did not show benefit.
Neither is a personal schedule or calculator input.